JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the competitive BTK inhibitor market. Latest Ratings for BGNE Date Firm Action From To ...
Read Also
- Walmart is selling a popular $279 grill for only $147, and shoppers say it's 'wonderful'
- HubSpot To Gain Market Share With AI Innovations and Strong Retention, Bullish Analyst Says
- 5 Analysts Have This To Say About Trupanion
- In-Depth Examination Of 7 Analyst Recommendations For Avery Dennison
- Peering Into Carpenter Tech's Recent Short Interest
- (KD) - Analyzing Kyndryl Hldgs's Short Interest
- (DAL) - Analyzing Delta Air Lines's Short Interest
- Stock movers after Fed rate cut: Tesla, Salesforce, Darden Restaurants, and more
- 5 Analysts Assess GEO Group: What You Need To Know
- What's Going On With Hut 8 Shares Thursday?
Latest Benzinga
- HubSpot To Gain Market Share With AI Innovations and Strong Retention, Bullish Analyst Says
- 5 Analysts Have This To Say About Trupanion
- In-Depth Examination Of 7 Analyst Recommendations For Avery Dennison
- Peering Into Carpenter Tech's Recent Short Interest
- (KD) - Analyzing Kyndryl Hldgs's Short Interest
- (DAL) - Analyzing Delta Air Lines's Short Interest
- 5 Analysts Assess GEO Group: What You Need To Know
- What's Going On With Hut 8 Shares Thursday?
- Why Hewlett Packard (HPE) Stock Is Seeing Blue Skies
- This Robinhood Analyst Raises Forecast By 17% On Retail Trading and Crypto Expansion - Here's Why